High expression quantities of the CD38 antigen on MM PCs are indispensable for anti-CD38 activity [36]; however, during daratumumab administration, CD38 expression reduces via JAK-STAT3 signaling pathway alterations [37] and return to basal concentrations 3–6 months after daratumumab suspension. Here, CD38 is linked to Miyoshi myopathy.